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Abstract 
 
Drug discovery strategies are divided into two types of approaches, target-oriented 
screens and phenotypic screens. The phenotypic approach is a strategy whereby 
pharmaceutical research focuses on compounds that demonstrate phenotypic efficacy 
against a disease model. However, clarification of the molecular mechanism and targets 
of bioactive compounds can be a bottleneck for drug development using this approach. 
The objectives of this study were to elucidate the molecular mechanisms of action and 
the selectivity profiles of two drug candidates, T-162559 and TAK-242, which were 
optimized or discovered by phenotypic assays in myocardial infarction (MI) and sepsis.  
T-162559 was identified in an in vitro assay monitoring platelet swelling induced by 
acidosis as a Na
+
/H
+
 exchanger (NHE) inhibitor and demonstrated cardioprotective 
effects in vivo in ischemia-reperfusion injury models. The hypothesis for the mechanism 
of action for T-162559 is that the main molecular target is an NHE1 isoform that plays a 
role in intracellular pH (pHi) regulation after acidosis. To establish an assay system for 
the human NHE1 isoform, NHE-deficient Chinese hamster ovary (CHO)-K1 cells were 
isolated by a proton suicide method of selection, since most cells express NHEs. An 
NHE assay system was then developed to monitor pH recovery of cells from acidosis 
after NH4Cl prepulse treatment. This assay system demonstrated that T-162559 is a 
selective and potent inhibitor of NHE1. 
TAK-242 was identified in vitro in a cell-based assay monitoring nitric oxide (NO) 
and cytokine production from lipopolysaccharide (LPS)-treated macrophages 
(RAW264.7). This compound had a therapeutic effect in vivo in endotoxin shock models. 
Initial studies on effects of TAK-242 on the production of inflammatory mediators 
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induced with various Toll-like receptor (TLR) ligands were carried out in vitro with the 
RAW264.7 macrophage cell line. These studies showed that TAK-242 selectively 
suppressed TLR4 ligand-induced production of NO, while little effect was noted for 
other TLR ligand activities. TAK-242 inhibited LPS-mediated nuclear factor-kappaB 
(NF-B) activation in HEK293 cells transiently expressing TLR4 and its co-receptors, 
myeloid differentiation protein-2 (MD2) and cluster of differentiation (CD) 14. 
TAK-242 also inhibited ligand-independent NF-B activation mediated by TLR4 
overexpression or chimeric TLR4 receptors consisting of the extracellular domain of 
CD4 and intracellular domain of TLR4. These results indicated that TAK-242 
suppresses TLR4-signaling mediated by the intracellular domain. 
In conclusion, T-162559 and TAK-242 were shown to specifically target NHE1 and 
TLR4, respectively, and these data suggest that these compounds have promise as 
treatments for NHE1 and TLR4-dependent diseases. 
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General Introduction 
 
There are two different approaches for drug discovery, target-oriented screens and 
phenotypic screens. Target-oriented drug discovery, called reverse pharmacology, 
begins with identification of a target relevant to a disease of interest After identification 
and validation of the target, a biochemical assay system is established based on the 
function of the target. Drug screening is then conducted using a diverse compound 
library. After the selection of compounds with positive activity, lead optimization is 
carried out, typically utilizing medicinal chemistry methodologies to improve potency, 
efficacy, selectivity and bioavailability. Lead compounds with potent activity are then 
evaluated further in in vitro cell-based assays and in vivo disease models. Compounds 
with acceptable preclinical potency and efficacy are then moved into investigational 
new drug (IND)-enabling studies, including toxicology and safety pharmacology studies 
to enable initiation of clinical trials. Phenotypic drug discovery, termed forward 
pharmacology, screens test compounds by monitoring phenotypic changes in systems 
that are related to disease processes. This approach has been used historically for drug 
discovery, with subsequent identification of the molecular targets being affected by the 
compounds. Recent scientific discoveries and technological advancements, such as 
high-throughput screening, structure-based drug design, combinatorial chemistry, and 
the studies of the human genome and the role of gene products in various diseases, have 
shifted the focus of drug discovery and development to target-oriented approaches in 
biotechnology and pharmaceutical industries. 
 An advantage of target-oriented drug discovery is that the molecular target is 
defined at the initial stage of drug discovery. This enables the development of 
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biochemical or biophysical assays with recombinant proteins or cells that allow 
informed medicinal chemistry efforts to develop active compounds utilizing techniques 
such as molecular modeling and structure-based drug design. Pharmacological or 
pharmacodynamic experiments can be designed based on the profile of the target 
molecule. Despite these advantages, in many cases, selected compounds do not show 
sufficient efficacy in disease models or in patients. This can occur for two general 
reasons. First, the molecular target, while correlated with presence of the disease, may 
not play a primary role in its pathogenesis. Second, the drug candidate that is supposed 
to affect the target lacks adequate potency for a variety of reasons, such as 
pharmacokinetic behavior, toxicity, poor affinity, or lack of selectivity. Despite 
technological advancements in drug and target discovery, the productivity of drug 
discovery has been disappointing, particularly for the discovery and successful 
development of first in class drugs for a given target or indication. Consequently, 
phenotypic approaches have been reimplemented to contribute to the discovery of new 
targets and first in class drugs. For example, the discovery of peroxisome 
proliferator-activated receptor gamma ligands was facilitated by studies with 
thiazolidinediones, which were identified in phenotypic screens targeting diabetes 
(Karak et al., 2013). A key advantage of the phenotypic approach is that 
pharmacological research can be initiated using compounds that have shown efficacy in 
relevant cell-based systems in vitro or animal models in vivo. This approach is 
straightforward for the identification of compounds with promising phenotypic activity. 
A key requirement for a sound phenotypic-based discovery approach is the 
establishment of physiologically relevant assay systems that can serve as a translational 
bridge to clinical efficacy and safety. The phenotypic approach holds the promise of 
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identifying new therapeutic modalities and molecular pathways for untreatable diseases 
(Eder et al., 2014). However, a caveat is that the molecular mechanisms for compounds 
discovered by phenotypic screens may be poorly characterized. An understanding of the 
molecular target can facilitate utilization of advantages of the target-oriented approach. 
Furthermore, insights on the potential efficacy and toxicity of compounds that affect the 
target protein can be assessed using transgenic or knockout animals before initiating 
clinical trials. However, identification of the molecular target is still a bottleneck for this 
approach.  
  In this study, the molecular mechanisms of action and the selectivity profiles are 
characterized for T-162559 and TAK-242 which were optimized or discovered by 
phenotypic assays using native cells. These small-molecule compounds are being 
developed for the treatment of myocardial infarction and sepsis, respectively, which are 
life-threatening diseases with unmet medical needs. This study demonstrates that 
T-162559 and TAK-242 are selective inhibitors of NHE1 and TLR4, respectively. 
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Chapter I: Molecular Mechanism of Action of T-162559 
 
1. Introduction 
Myocardial infarction (MI) is a life-threatening disease caused by the loss of blood 
perfusion to a specific region of the heart. Acute MI occurs when plaque deposits that 
have developed in patients with coronary artery disease break up and fragments lodge in 
arteries blocking blood flow to the heart. Prompt emergency medical attention is crucial 
for the treatment of acute MI, including treatment with antithrombotics and angioplasty 
to restore and protect blood flow. However, MI remains a leading cause of morbidity 
and mortality worldwide, with approximately 600,000 deaths in the United States every 
year (Murphy et al., 2013). Furthermore, reperfusion therapy has the risk of additional 
myocardial damage by causing acute ischemia-reperfusion injury. Thus, there is still a 
high medical unmet need for more effective treatments for MI. The pathological 
consequences of MI arise from the detrimental effects of acute ischemia-reperfusion 
injury, which leads to cardiomyocyte cell death, cardiac failure, arrhythmias and patient 
death. Thus, more effective therapeutic approaches are needed to protect the heart from 
acute ischemia–reperfusion injury to reduce myocardial infarct size (Sluijter et al., 
2014). During ischemia, accumulation of lactate in cells results in acidosis and cellular 
swelling with plasma membrane blebbing. Subsequently, the swollen cells develop 
physical defects in their cell membranes and rupture. These features of cell injury with 
cell swelling have been shown to involve cardiomyocyte cells subjected to hypoxia in 
vitro and cardiac muscle during MI in vivo. The underlying membrane damage to 
ischemic myocyte cells has served as the basis for the diagnosis of MI (Buja et al., 
1998). 
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T-162559 is being developed as a small molecule NHE inhibitor for the treatment of 
MI (Kusumoto et al., 2002, Fukumoto et al., 2002). To generate an NHE inhibitor, a 
cell-based assay was established by monitoring an increase in light transmission that is 
associated with acidosis-induced swelling in platelets. Lead optimization was initiated 
with an aminoguanidine derivative having an IC50 value of 2.3M. After optimization, 
a potent inhibitor, T-162559 was identified. This compound inhibited platelet cell 
swelling with an IC50 value of 13 nM, and had a protective effect on perfused rat hearts 
after global ischemia and reperfusion. Intravenous administration of T-162559 (0.03 and 
0.1 mg/kg) significantly inhibited MI progression induced by left coronary artery 
occlusion and reperfusion in rabbits (Kusumoto et al., 2002). These results 
demonstrated that T-162559 is a promising drug candidate for the treatment of MI. 
Intracellular pH is regulated by Na
+
/H
+
 exchangers (NHEs), which are ion transporters 
that mediate Na
+
 and H
+ 
exchange across lipid bilayers in prokaryotes and eukaryotes. 
NHEs participate in various cellular functions such as the maintenance of pHi and cell 
volume. The Na
+
 electrochemical gradient is utilized by NHEs to remove H
+
 from cells 
with a stoichiometric coupling ratio of 1 Na
+
:1 H
+
. Hydropathy analysis of NHE 
predicts that they have similar membrane topologies, with an N-terminal membrane 
domain consisting of twelve transmembrane segments and a divergent C-terminal 
cytoplasmic domain (Pullikuth et al., 2003, Orlowski et al., 2004) (Fig. 1-1).  
Currently, thirteen conserved NHE isoforms are known in mammals. Human NHEs 
are encoded by the solute carrier (SLC) classification of the transporter 9 family. NHE 
isoforms are divided into two classes, plasma membrane NHEs (NHE1–NHE5) and 
organelle NHEs (NHE6–NHE9) (Fuster et al., 2014). Although NHE1 is ubiquitously 
expressed, other plasma membrane NHEs show tissue specific expression profiles 
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(Table1-1). NHE2–NHE4 isoforms are predominantly expressed in epithelial cells of 
the kidney, small intestine, and stomach, and NHE5 is primarily expressed in the brain 
(Wakabayashi et al., 2013). In contrast, NHE6–NHE9 are expressed in intracellular 
organelles, including the trans-Golgi network, endosomes, and mitochondria in various 
tissues where they function to control organelle luminal pH by K
+
/H
+
 exchange (Hill et 
al., 2006). 
The NHE1 isoform is the most well-characterized isoform of the NHE family. The 
amino acid identity of NHE1 among human plasma NHE isoforms ranges from 36% to 
49% (Table 1-1). Human NHE1 consists of 815 amino acids, with residues 1 to 500 
comprising the membrane-associated domain and residues 501 to 815 comprising the 
cytoplasmic domain (Fliegel et al., 1993). The membrane domain of NHE1 is important 
for ion transport, whereas the cytoplasmic domain is implicated in regulation of Na
+
/H
+
 
exchange activity. The cytoplasmic domain of NHE1 regulates NHE activity by 
interacting with Ca
2+
-binding proteins, protein kinases, phosphatases, and cytoskeletal 
proteins (Wakabayashi et al., 2013). 
 NHE1 plays a critical role in controlling intracellular acidosis. After myocardial 
ischemia, tissue pH significantly declines and returns to normal after reperfusion. 
During ischemia-reperfusion, excessive activation of NHE1 by a decrease in pHi causes 
a significant elevation in intracellular Na
+
 (MacLeod, et al., 1991, Karmazyn et al., 
1999). The increase in intracellular Na
+
 leads to Ca
2+
 overload through reverse-mode 
activation of the Na
+
/Ca
2+
 exchanger (NCX) (Lazdunski et al., 1985, Guarnieri, 1987, 
Wier, 1990) and Ca
2+
 overload is thought to be a major mechanism involved in the 
development of irreversible damage during ischemia-reperfusion. A variety of NHE 
inhibitors have been developed, or are currently being developed, for the treatment of 
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ischemia-reperfusion injury. Acylguanidine derivatives such as cariporide and eniporide 
have been reported to be selective inhibitors of NHE1, and these compounds have 
shown cardioprotective effects in ischemia-reperfusion models (Counillon et al., 1993a, 
Scholz et al., 1995, Gumina et al., 1998, Yamamoto et al., 2000).  
Na
+
/H
+ 
exchanger 1 (NHE1) inhibitors, including the acylguanidine derivatives, 
caliporide and eniporide, inhibit platelet swelling and have a protective effect in 
ischemic injury (Kusumoto et al., 2002). T-162559 has a protonated guanidine structure 
and mimics a sodium cation hydrated with three water molecules. While cell-based 
discovery approach using platelets was used to identify T-162559, this is also 
chemistry-based approach since structurally related compounds with known NHE1 
activity can serve as a starting point for lead optimization. On the basis of the effects of 
related compounds, molecular target of this compound was expected to be NHE1. To 
characterize the molecular mechanism of action of T-162559, its effect on human NHE 
isoforms were investigated. An assay to measure Na
+
/H
+
 exchange activity was 
established by monitoring intracellular pH alterations with cells stably expressing 
human NHE isoforms (hNHE1, hNHE2, and hNHE3). We investigated the effects of a 
novel aminoguanidine derivative, T-162559, on human NHE isoforms and demonstrated 
that T-162559 is a selective inhibitor of the hNHE1 isoform with greater potency than 
cariporide and eniporide. 
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2.  Materials and Methods 
2.1. Compounds  
T-162559 ((5E,7S)-[7-(5-fluoro-2-methylphenyl)-4-methyl-7,8-dihydro-5(6H) 
-quinolinylideneamino] guanidine dimethanesulfonate), T-162561 ((5E,7R)- 
[7-(5-fluoro-2-methylphenyl)-4-methyl-7,8-dihydro-5(6H)-quinolinylideneamino] 
guanidine dimethanesulfonate), cariporide, and eniporide were synthesized at Takeda 
Pharmaceutical Company  (Fig.1-2). These compounds were dissolved in dimethyl 
sulfoxide (DMSO). 
 
2.2. Plasmids 
 cDNAs encoding hNHE1, hNHE3 and human Na
+
:HCO3
-
 cotransporter 1 (hNBC1) 
were isolated by polymerase chain reaction (PCR) and subcloned into the mammalian 
expression vector pMSR-neo, which contained the SRpromoter. cDNAs encoding 
hNHE2 and human NCX1 were isolated by PCR and subcloned into the mammalian 
expression vector pcDNA3.1/Zeo (Invitrogen), which contained the cytomegalovirus 
(CMV) promoter.  
 
2.3. Cell culture 
CHO-K1 cells and their NHE-deficient cells were maintained in Ham’s F-12 medium 
(Life Technologies, Inc., USA.) containing 10% fetal calf serum and 50 g/ml 
gentamicin (Life Technologies, Inc., USA.) in a humidified 5% CO2 incubator at 37 °C.   
 
2.4. Isolation of NHE-deficient mutant cells 
The NHE-deficient mutant was isolated by the proton suicide technique (Pouyssegur 
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et al., 1984). CHO-K1 cells were initially mutagenized with 150 g/ml ethylmethane 
sulfonate (EMS) (Aldrich) in the culture medium for 16 h. Then, cells were trypsinized 
and incubated in Li
+
 saline solution (130 mM LiCl, 5 mM KCl, 1 mM MgSO4, 2 mM 
CaCl2, 5 mM glucose, 20 mM HEPES, pH7.4) for 2 h at 37 °C. After Li
+
 loading, Li
+
 
saline solution was removed by centrifugation. Then, the cell pellet was washed with 
and incubated in choline-Cl saline solution (130 mM choline-Cl, 5 mM KCl, 1 mM 
MgSO4, 2 mM CaCl2, 5 mM glucose, 20 mM 2-(N-morpholino) ethanesulfonic acid, 
pH5.5) for 60 min at 37 °C. Cells were centrifuged, suspended and transferred to the 
culture medium. After 4 days of culture, resistant cells were trypsinized and subjected to 
two cycles of selection. NHE-deficient clones were selected and a single clone was 
isolated by limited dilution.   
 
2.5. Transfection 
Transfection was performed with NHE-deficient CHO-K1 cells (8x10
6
 cells per 800 
l) for hNHE1, hNHE2, hNHE3, and hNBC1, and with wild-type CHO-K1 cells (8x106 
cells per 800 l) for hNCX1 by electroporation using a Gene Pulser (Bio-Rad 
Laboratories) at 250 mV and 960 F. Stable transformants of hNHE1, hNHE3, and 
hNBC1 were selected in the presence of 500 g/ml geneticin (Life Technologies, Inc., 
USA).  Stable transformants of hNHE2 and hNCX1 were selected in the presence of 
250 g/ml zeocin (Life Technologies, Inc., USA).  
 
2.6. Measurement of Na
+
/H
+
 exchange activity 
Na
+
/H
+
 exchange activity was determined by using the membrane-permeable 
acetoxymethyl (AM) ester form of the pH-sensitive fluorescent indicator 
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2’,7’-bis(2-carboxyethyl)-5(6)-carboxyfluorescein (BCECF) to measure the 
Na
+
-dependent recovery of pHi from NH4Cl prepulse acidification (Nakanishi et al., 
1991).  Aliquots of 5x10
4
 cells were seeded in WhiteClini Plates (white 96-well plates, 
Labsystems, Finland) and cultured at 37 °C overnight.  After removal of the medium, 
the cells were loaded with 5 M BCECF-AM (Wako Pure Chemical Ind., Ltd., Japan) 
for 30 min at 37 °C. Cells were washed with Na
+
 solution (140 mM NaCl, 5 mM KCl, 1 
mM CaCl2, 1 mM MgSO4, 10 mM glucose, 10 mM HEPES, pH7.4) and subsequently 
incubated in Na
+
 solution containing 25 mM NH4Cl for 10 min at 37°C. Acid loading 
was performed by washing cells with Na
+
-free solution (140 mM 
N-methyl-D(-)-glucamine, 5 mM KCl, 1 mM CaCl2, 1 mM MgSO4, 10 mM glucose, 10 
mM HEPES, pH7.4). Then, 47.5 l of Na+-free solution and 2.5 l of test compounds 
were added to the cells, followed by incubation for 5 min. Fluorescence was measured 
by using a fluorescence drug screening system, FDSS-2000 (Hamamatsu Photonics, 
Ltd., Japan). Aliquots of 200 l of Na+ solution were added to the cells and the 
fluorescence ratio (450 nm/490 nm) was monitored. The initial velocity of pHi recovery 
via NHE was calculated using linear regression of the initial data points (10 s for NHE1, 
40 s for NHE2 and NHE3). An inhibitory activity of NHE inhibitors was evaluated by a 
reduction of the velocity. For calculation of the inhibition, pHi recovery with DMSO in 
cells expressing NHE isoforms was equated with 100% activity and pHi recovery with 
DMSO in NHE-deficient cells was equated with 0% activity.  
 
2.7. Measurement of Na
+
:HCO3
-
 cotransport activity 
Na
+
:HCO3
-
 cotransport activity was determined using BCECF-AM to measure the 
Na
+
-dependent recovery of pHi from NH4Cl prepulse acidification (Burnham et al., 
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1997). Cells were seeded at 5 x 10
4
 cells in WhiteClini Plates (white 96-well plates, 
Labsystems, Finland) and cultured at 37 °C overnight. After removal of the medium, 
cells were loaded with 5 M BCECF-AM (Wako, Japan) for 30 min at 37 °C. Cells 
were washed with solution A (140 mM tetramethyl ammonium chloride, 25 mM 
KHCO3, 0.8 mM K2HPO4, 0.2 mM KH2PO4, 1 mM CaCl2, 1 mM MgCl2, 10 mM 
HEPES, pH7.4) and then incubated in solution B (100 mM tetramethyl ammonium 
chloride, 40 mM NH4Cl, 25 mM KHCO3, 0.8 mM K2HPO4, 0.2 mM KH2PO4, 1 mM 
CaCl2, 1 mM MgCl2, 10 mM HEPES, pH7.4) for 10 min at 37°C. Acid loading was 
performed by washing cells with solution A. Then, 47.5 l of solution A and 2.5 l of 
test compounds were added to the cells, followed by incubation for 5 min.  
Fluorescence was measured with FDSS-2000. Aliquots of 200 l of solution C (115 mM 
NaCl, 25 mM KCl, 25 mM NaHCO3, 0.8 mM K2HPO4, 0.2 mM KH2PO4, 1 mM CaCl2, 
1 mM MgCl2, 10 mM HEPES, pH7.4) were added to the cells and fluorescence ratio 
(450 nm/490 nm) was monitored for 5 min.  
 
2.8. Measurement of Na
+
/Ca
2 +
 exchange activity 
Na
+
/Ca
2+
 exchange activity was determined using the membrane-permeable AM ester 
form of the Ca
2+
-sensitive fluorescent indicator FuraPE3 to measure cytoplasmic Ca
2+
 
alterations (Komuro et al, 1992, Fang et al., 1998). Cells were seeded at 5x10
4
 cells in 
Opaque Plates (white 96-well plates, Corning Coster) and cultured at 37°C overnight. 
After removal of the medium, cells were loaded with 20 M FuraPE3-AM (Wako, 
Japan) for 60 min at 37 °C. Cells were washed three times with physiological salt 
solution (PSS) (120 mM NaCl, 20 mM NaHCO3, 5 mM KCl, 1 mM CaCl2, 1 mM 
MgCl2, 20 mM HEPES, pH7.4).  Then, 188 l of PSS and 2.0 l of test compounds 
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were added to the cells, followed by incubation for 5 min. Fluorescence was measured 
with FDSS-2000. Aliquots of 10 l of phosphate-buffered saline (PBS) containing   
200 M gramicidin (Sigma, USA) were added to the cells and the fluorescence ratio 
(340 nm/380 nm) was monitored for 15 min. 
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3.  Results 
3.1. Functional expression of human NHE (hNHE) isoforms in NHE-deficient 
CHO-K1 cells  
Na
+
/H
+
 exchangers are endogenously expressed in most mammalian cells. We 
isolated an NHE-deficient Chinese hamster ovary (CHO)-K1 mutant using the proton 
suicide selection method (Poussegur et al., 1984). The cell growth of the NHE-deficient 
mutant was not significantly different from that of the wild-type in regular medium 
buffered at pH 7.4 with CO2/HCO3
-
 (data not shown).   
NHE-deficient CHO-K1 cells that were transfected with human NHE 
isoform-expressing plasmids and stable transformants were isolated. Na
+
/H
+
 exchange 
activity was determined using BCECF-AM to measure Na
+
-dependent recovery of the 
pHi after NH4Cl prepulse acidification. pHi was measured with a fluorescent screening 
system, FDSS-2000 (Hamamatsu Photonics), which was able to measure fluorescence 
alterations in real time in a 96-well microplate using a charge-coupled device (CCD) 
camera.  
Human NHE isoforms, hNHE1, hNHE2, and hNHE3, expressed in NHE-deficient 
CHO-K1 cells had functional Na
+
/H
+
 exchange activity, whereas NHE-deficient cells 
showed no change in pHi after the addition of external Na
+
 (Fig. 1-3). Especially, NHE1 
expressing cells showed a rapid recovery of pHi after NH4Cl prepulse acidification as 
compared with hNHE2- and hNHE3-expressing cells. These results support the 
conclusion that NHE1 is the primary isoform involved in the recovery of pHi and the 
entry of Na
+
 during cellular acidosis.   
 
3.2. Selective inhibition of the hNHE1 isoform by cariporide, eniporide, and 
T-162559 
Selectivity of the NHE inhibitors cariporide and eniporide was assessed on the 
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various human NHE isoforms. In the Na
+
-dependent pHi recovery assay, cariporide and 
eniporide inhibited hNHE1 in a concentration-dependent manner (Fig. 1-4). The NHE1 
IC50 values for cariporide and eniporide were 30 nM and 4.5 nM, respectively (Table 
1-2). Cariporide and eniporide inhibited hNHE2 with low potencies (IC50 values of 4.3 
M and 2.0 M, respectively), and did not inhibit hNHE3 at concentrations ranging up 
to 100 M.  
The potency of a novel synthetic NHE inhibitor, the aminoguanidine derivative 
T-162559, was evaluated in the assay for effects on human NHE isoforms. In the 
Na
+
-dependent pHi recovery assay, T-162559 inhibited hNHE1 in a 
concentration-dependent manner (Fig. 1-4) with an IC50 of 0.96 nM, which was 30-fold 
and 4.7-fold lower than the IC50 values for cariporide and eniporide, respectively (Table 
1-2). T-162559 had weak inhibitory effects on hNHE2 and hNHE3 (IC50 values of 430 
nM and 11 M, respectively). The IC50 values of this compound for hNHE2 and hNHE3 
were 450-fold and 11000-fold higher, respectively, than for hNHE1. We also evaluated 
the potency of T-162561, the R enantiomer of T-162559 (Fig. 1-4). The inhibitory effect 
of T-162561 on hNHE1 was decreased 36-fold relative to the S enantiomer, T-162559 
(35 nM IC50 value of T-162561 for hNHE1), whereas the IC50 value of T-162561 for 
hNHE2 was similar to that of T-162559 (Table 1-2).   
 
3.3. Effects of T-162559 on ion transporters hNBC1 and hNCX1  
To investigate the effects of T-162559 on other ion transporters, we isolated cells 
stably expressing the human Na
+
:HCO3
-
 cotransporter (hNBC1) and the human cardiac 
Na
+
/Ca
2+
 exchanger (hNCX1).  
hNBC1 cotransporter activity was measured by monitoring Na
+
-dependent pH 
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recovery after NH4Cl prepulse acidification in the presence of HCO3
-
. After the addition 
of external Na
+
, a significant increase in pHi was observed in cells expressing hNBC1, 
whereas non-transfected NHE-deficient CHO-K1 cells only showed a slight increase in 
pHi (Fig.1-5A). In this assay system, T-162559 did not significantly affect the initial 
rate of pHi recovery mediated by hNBC1 at 100 M (Fig. 1-5A).  
Na
+
/Ca
2+
 exchange activity of hNCX1 expressed in CHO-K1 cells was quantified by 
assaying Ca
2+
 influx caused by an increase in intracellular Na
+
 in the presence of the 
Na
+
 ionophore gramicidin. After reverse-mode activation of hNCX1 by an increase in 
intracellular Na
+
, a slow and sustained increase in intracellular Ca
2+
 was observed in 
cells transfected with hNCX1, whereas non-transfected CHO-K1 cells showed no 
change in intracellular Ca
2+
 (Fig. 1-5B). In this assay system, 100 M T-162559 did not 
affect hNCX1 (Fig. 1-5B). 
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4.  Discussion 
Myocardial infarction is defined as myocardial cell death due to prolonged ischemia. 
Na
+
/H
+
 exchange plays an important role in the development of irreversible cellular 
damage during ischemia-reperfusion. The primary mechanism of myocardial protection 
by NHE1 inhibitors in ischemia-reperfusion is likely by delaying the progression of 
ischemic injury, resulting in a decrease in infarct size even after long periods (>4 hrs) of 
ischemia (Avkiran, 1999). Pharmaceutical companies have been developing NHE 
inhibitors for the treatment of ischemia-reperfusion injury for the past several years 
(Scholz et al., 1995; Gumina et al., 1998; Counillon et al., 1993a; Yamamoto et al., 
2000). Cariporide is the first NHE inhibitor that was evaluated in clinical trials. Clinical 
studies with cariporide showed cardioprotective effects in patients with acute anterior 
MI who were also treated with direct percutaneous transluminal coronary angioplasty 
(Rupprecht et al., 2000). 
Several ion transporters and channels are involved in the regulation of platelet cell 
volume (Sarkadi et al., 1991). Activation of NHE1 results in platelet swelling associated 
with a reversal in the transport of cytoplasmic H
+
 and extracellular Na
+
 under acidified 
intracellular conditions (Livne et al., 1987). NHE1 constitutes a major pathway for Na
+
 
influx into the cell, and is coupled to Cl
−
 and H2O uptake to ensure restoration of cell 
volume following cell shrinkage (Fuster et al., 2014). Among NHE isoforms, NHE1 is 
expressed in human platelets (Aharonovitz et al., 1996), and cariporide inhibits human 
platelet NHE activity (Weichert et al., 1997, Kusumoto et al., 2002). These results 
suggest that acidosis-induced cell swelling of platelets is mediated through NHE1. 
 To clarify the hypothesis that T-162559 targets NHE1, a fluorescence-based 
screening system was developed. Cariporide and eniporide showed selective inhibition 
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of hNHE1, with IC50 values similar to those previously reported for rat NHE isoforms 
(Scholz et al., 1995, Gumina et al., 1998). These results are consistent with previous 
reports that the amiloride binding domain in the fourth transmembrane segment of NHE 
isoforms is conserved between human and rat sequences (Wakabayashi et al., 1997, 
Counillon et al., 1993b, Counillon et al., 1997). Taken together, these results validated 
the assay system used for evaluation of NHE isoforms and their inhibitors. 
T-162559 showed selective inhibition of hNHE1 with greater potency than cariporide 
and eniporide (IC50 value of 0.96 nM). Although NHE inhibitors, such as S3226 
(Schwark et al., 1998), SL 59.1227 (Lorrain et al., 2000), TY-12533 (Aihara et al., 
2000), and SM-20550 (Yamamoto et al., 2000) have been developed, the reported 
NHE1 IC50 values of these compounds are 3.6 M (S3226), 3.3 nM (SL 59.1227), 17 
nM (TY-12533), and 10 nM (SM-20550). T-162559 is a more potent NHE1 inhibitor 
when compared to these compounds. This potent activity was observed not only in vitro, 
but also in vivo. In a rat model of MI induced by coronary occlusion and reperfusion, 
intravenous administration of T-162559 resulted in a greater degree of reduction in 
infarct size, than seen for cariporide and eniporide (Kusumoto et al., 2002). The 
inhibitory effect of the R enantiomer T-162561 on hNHE1 was 36-fold less potent than 
that of the S enantiomer, T-162559, whereas the IC50 value of the R enantiomer for 
hNHE2 was similar to that of the S enantiomer. This result suggests that the 
configuration of the asymmetric carbon of T-162559 is important for tight binding to 
hNHE1. Previously reported NHE inhibitors, including amiloride, cariporide, and 
eniporide, contain the same basic acylguanidine moiety. The aminoguanidine derivative 
T-162559 is a potent non-acylguanidine class of NHE1 inhibitor with cardioprotective 
activity. The activity of T-162559 based on its unique structure may contribute to the 
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efficacy noted under prolonged ischemia-reperfusion insult. 
NHE1-expressing cells recovered rapidly from cellular acidosis when compared to 
hNHE2- and hNHE3-expressing cells. Additionally, NHE1 is the dominant isoform in 
cardiac tissue and its mRNA expression is elevated in response to cardiac injury 
(Humphreys et al., 1999, Dyck et al., 1995, Gan et al., 1999, Piper et al., 1996). The 
sarcolemmal NHE activity of human ventricular myocytes is due to the NHE1 isoform 
and is inhibited by cariporide (Yokoyama et al., 2000). Sarcolemmal NHE activity is 
significantly greater in recipient hearts with chronic end-stage heart failure than it is in 
non-diseased donor hearts (Yokoyama et al., 2000). Other plasma membrane-expressed 
human NHE isoforms have tissue-specific expression patterns. Therefore, selective 
inhibition of the NHE1 isoform may offer a novel specific approach for the treatment of 
cardiac injury during ischemia-reperfusion. Further evidence supporting the target 
potential of NHE1 for the treatment of MI was demonstrated by genetic ablation of 
NHE1 in mice, which protected their hearts from ischemia-reperfusion injury (Wang et 
al., 2003).  
Amiloride and its derivatives are non-specific NHE inhibitors because these 
compounds have been shown to inhibit Ca
2+
 current, Na
+
 current, K
+
 current, and 
Na
+
/Ca
2+
 exchangers (Pierce et al., 1993, Lai et al., 1994). Na
+
:HCO3
-
 cotransport and 
Na
+
/Ca
2+
 exchange are thought to play important roles in ischemia-reperfusion injury 
(MacLeod, 1991, Lazdunski et al., 1985, Guarnieri, 1987, Wier, 1990, Schafer et al., 
2000). However, T-162559 did not affect Na
+
:HCO3
-
 cotransport and Na
+
/Ca
2+
 
exchange, demonstrating that T-162559 is a potent and specific inhibitor of hNHE1.  
In conclusion, we demonstrated that the molecular target of T-162559 is the NHE1 
isoform. Our findings characterized the therapeutic activity of T-162559 on cardiac 
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injury in experimental ischemia-reperfusion injury models. Myocardial ischemia 
induces cellular acidosis by accumulation of lactate in cardiomyocytes. NHE is 
subsequently activated during ischemia and elevates the intracellular Na
+
 concentration 
by removing H
+
 from the cell with a 1 Na
+
:1 H
+
 coupling stoichiometry. After 
reperfusion, the extracellular protons are washed away. Hence, the resulting pH gradient 
across the cell membrane leads to activation of NHE1. As a result, concomitant 
increases in Ca
2+
 influx occur by reverse mode activation of NCX, which is functionally 
coupled with NHE1. Ca
2+
 overload then results in irreversible cellular damage by 
activation of Ca
2+
-dependent proteases such as calpain and caspases. Furthermore, 
mitochondrial Ca
2+
 accumulation leads to adverse cellular effects, facilitating 
mitochondrial membrane permeabilization and energetic collapse (Garcia-Dorado et al., 
2012). Therefore, inhibition of Na
+
/H
+
 exchange by T-162559 protects ischemic cells 
from Ca
2+
 overload.  
NHE1 forms a complex with NCX1 through integrin αIIbβ3 (Yi et al., 2009). This 
interaction on the plasma membrane enables functional coupling between NHE1 and 
NCX1. Thus, NHE1 can generate local high intracellular sodium concentrations, which 
activate the reverse mode of NCX1, driving calcium influx. The ischemic condition 
leads to decreased intracellular concentrations of ATP, resulting in a decrease in 
ATP-dependent ion transport systems, including the Na
+
/K
+
-ATPase pump that 
transports K
+
 into the cell and Na
+
 out of the cell. This causes cell membrane 
depolarization due to loss of hyperpolarizing currents (Ikenouchi et al., 1993). Thus, the 
reverse mode of NCX is activated under conditions such as intracellular Na
+
 
accumulation via NHE1 and membrane depolarization during ischemia-reperfusion 
injury. The observed therapeutic effects of T-1625592 in cardiac injury models during 
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ischemia-reperfusion are believed to be due to suppression of NHE1 in the ischemic 
heart. Previous studies using animals models of MI indicate that NHE1 is involved in 
the elevation of intracellular Na
+
 and Ca
2 +
 during prolonged myocardial ischemia. In 
fact, cariporide has been reported to suppress intracellular Ca
2+
 transients in an 
ischemia-reperfusion rat heart model (Strömer et al., 2000). Pharmacological studies 
with an NCX inhibitor (Takahashi et al., 2003), a calpain inhibitor (Cai et al., 2012) and 
a mitochondrial permeability transition pore (mPTP) inhibitor, Cyclosporin A 
(Hausenloy et al., 2012) demonstrated its cardioprotective effects on 
ischemia-reperfusion injury. These results support our hypothesis regarding the 
molecular mechanism of action of T-162559.  
Clinical trials with NHE1 inhibitors have been carried out previously, but did not 
show sufficient clinical benefit despite promising preclinical results in animal models 
(Karmazyn et al., 2013). To achieve a favorable outcome in humans, translational 
studies are required to understand the molecular pathogenesis of MI patients. T-162559 
is a significantly more potent NHE1 inhibitor than other NHE1 inhibitors, and may have 
sufficient potency to be efficacious in the clinic. Since T-162559 is a selective inhibitor 
of human NHE1, further research with this compound should be carried out to evaluate 
its therapeutic potential, possibly in combination with other approved therapies.  
Recent studies suggest that NHE1 is also involved in cancer progression (Amith et al., 
2013). Extracellular acidification around tumor cells can induce apoptosis of nearby 
normal cells, resulting in selective survival of cancer cells. NHE1 causes a reversal of 
the pH gradient in many types of transformed and/or malignant cells and enhances 
survival of cancer cells. Therefore, NHE1 inhibitors may be potential therapies for the 
treatment of cancer. Hence, T-162559 would be a drug for the treatment of not only 
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ischemia-reperfusion injury and other cardiac diseases, but also other NHE1-mediated 
diseases. 
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5. Tables 
 
Table 1-1.  Plasma membrane NHE isoforms   
 
 
 
 
(Revised from Fuster et al., 2014)  
 
 
 
Table 1-2.  Inhibitory activities of small molecule NHE inhibitors against human 
NHE isoforms 
 
 
 
 
 
 
 
  
   IC50  values  (nM) 
Compound hNHE1 hNHE2 hNHE3 
T-162559  S (-) 0.96 430 11000 
T-162561  R (+) 35 310 >30000 
Cariporide 30 4300 >100000 
Eniporide 4.5 2000 >100000 
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6. Figures  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1. Structure and function of NHE   (Revised from Pullikuth et al., 2003) 
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Figure 1-2. Chemical structures of T-162559, cariporide, and eniporide. 
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Fig. 1-3.  Na
+
-dependent recovery of the intracellular pH in cells stably expressing 
human NHE isoforms. 
NHE-deficient CHO-K1 cells were transfected with human NHE isoform expression 
plasmids and stable transformants were isolated. Cells were loaded with BCECF-AM 
and then acidified by NH4Cl prepulse.  Recovery of pHi was initiated by the addition 
of external Na
+
 at the time indicated by the arrow.  The results shown are for cells 
expressing hNHE isoforms (○) and non-transfected cells (■).  Each data point 
represents the mean±S.E.(n=3).   
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Fig. 1-4.  Dose-response curves for inhibition of hNHE1, hNHE2, and hNHE3 by 
NHE inhibitors. 
NHE-deficient CHO-K1 cells expressing hNHE isoforms were loaded with 
BCECF-AM and then acidified by NH4Cl prepulse, followed by treatment with 
increasing concentrations of test compounds for 5 min. Initial velocity of pHi recovery 
was calculated in the initial data points (10 s for NHE1, 40 s for NHE2 and NHE3). An 
inhibitory effect of NHE inhibitor was evaluated by a reduction of the velocity of pHi 
recovery in the presence of test compounds. The results
 
are expressed as percentages of 
the initial velocity of pHi recovery in cells expressing the human NHE isoforms, 
hNHE1 (●), hNHE2 (▲), and hNHE3 (■). All data are means±S.E.(n=3).  
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Fig.1-5. Effects of T-162559 on human Na
+
:HCO3
-
 cotransporter (A) and human 
cardiac Na
+
/Ca
2+ 
exchanger (B).  
(A) NHE-deficient CHO-K1 cells were transfected with hNBC1 expression plasmid and 
a stable transformant was isolated. Cells were loaded with BCECF-AM and acidified by 
NH4Cl prepulse, followed by incubation with 100M T-162559 or DMSO for 5min.  
Recovery of pHi was initiated by the addition of external Na
+
 at the time indicated by 
the arrow in the presence of HCO3
-
. The results shown are for cells expressing hNBC1 
in the presence (○) or absence (▲) of 100 M T-162559 in DMSO, and for 
non-transfected cells (■). (B) CHO-K1 cells were transfected with hNCX1 expression 
plasmid and a stable transformant was isolated. Cells were loaded with FuraPE3-AM, 
followed by incubation with 100M T-162559 or DMSO for 5 min. The reverse-mode 
of Na
+
/Ca
2+
 exchange was activated by the addition of gramicidin at the time indicated 
by the arrow and the increase in intracellular Ca
2+
 was monitored for 15min.  The 
results shown are for cells expressing hNCX1 in the presence (○) or absence (▲) of 
100 M T-162559 in DMSO, and for non-transfected cells (■). Each data point 
represents the mean ± S.E. (n=3).   
 
 
 
 
(A) 
(B) 
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Fig.1-6. Working hypothesis of therapeutic action of T-162559 
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Chapter II: Molecular Mechanism of Action of TAK-242 
 
1. Introduction 
 Sepsis occurs when the host mounts a potent immune response against a 
life-threatening infection. Frequently, the immune response itself causes greater injury 
to the host than the actual infectious agent. Typically, this excessive immune reaction is 
triggered by bacterial infections; however, fungi, viruses, and parasites in the blood, 
urinary tract, lungs, or other tissues can also cause sepsis. Common symptoms of sepsis 
include fever, rapid heart rate, rapid breathing, flushed skin, hyperventilation, altered 
mental status, edema, hypotension, and shock. Severe sepsis is a medical emergency 
affecting up to 19 million individuals worldwide (Adhikari et al., 2011). Although sepsis 
is the most frequent cause of mortality in many intensive care units, no effective therapy 
is available, and the overall mortality rate still ranges from 30% to 50% in patients that 
go into septic shock. Hence, there is a high unmet medical need for managing this 
disorder (Martin et al, 2003, Angus et al, 2013). Although the systemic pathogenesis of 
sepsis is complicated, macrophages are thought to represent the first line of defense 
against infection in early inflammatory responses. Macrophages release a diverse range 
of inflammatory mediators, cytokines, chemokines, lipid mediators, and oxygen radicals. 
One of these mediators, nitric oxide (NO) modifies vascular tone and enhances 
hypotension (Cohen et al., 2002). 
 TAK-242 is being developed as a small molecule-based anti-sepsis drug. TAK-242 
was identified in a cell-based screening assay that measures lipopolysaccharide (LPS) 
induced NO and cytokine production using the RAW264.7 mouse macrophage cell line. 
The initial lead compound, a cyclohexene derivative, was identified in a chemical 
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library screen and lead optimization was carried out using the RAW264.7 cell-based 
assay. Among the various leads synthesized, TAK-242 had the greatest inhibitory 
activity, blocking the production of NO and inflammatory cytokines, such as TNF- and 
interleukin-6 (IL-6). Intravenous administration of TAK-242 at doses of 0.1 mg/kg or 
more suppressed the production of NO and various cytokines, including TNF-, IL-6, 
and interleukin-1beta (IL-1 in a mouse endotoxin shock model. TAK-242 also 
protected mice from LPS-induced death in a dose-dependent manner and all mice 
survived at a dose of 3 mg/kg. The minimum effective dose to protect mice from 
lethality in this model was 0.3 mg/kg, which was consistent with the observed inhibitory 
effects on the production of NO and cytokines (Yamada et al., 2005, Sha et al., 2007). 
Thus, TAK-242 is a promising therapeutic agent for the treatment of sepsis. Because 
TAK-242 was identified using a phenotypic assay, its molecular mechanism of action 
was unclear.  
The discovery of Toll-like receptors (TLRs) as primary sensors of microbial 
infections has led to significant advances in understanding the mechanisms of innate 
immunity and their relationship to sepsis. Ten TLR members have been identified in 
humans (Akira et al., 2006). Among human TLRs, ligands for TLR1-TLR9 have been 
identified through in vitro systems or knockout mice (Fig. 2-1). TLR2 dimerizes with 
TLR1 or TLR6 and recognizes the peptidoglycans and lipopeptides of gram-positive 
bacteria (Takeuchi et al., 2002). TLR4 detects gram-negative bacteria through 
recognition of the lipid A moiety of LPS (Poltorak et al., 1998; Hoshino et al., 1999). 
LPS recognition is mediated by four molecules, LPS binding protein (LBP), CD14, 
myeloid differentiation protein-2 (MD2), and TLR4 (Guha et al., 2001). LBP is thought 
to be a shuttle protein catalyzing LPS transfer from the outer membrane of 
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gram-negative bacteria to CD14 (Tobias et al., 1995). CD14 plays a role in docking LPS 
with the TLR4/MD2 complex. MD-2, a glycoprotein essential for the innate response to 
LPS, binds to LPS and the extracellular domain of TLR4 (Shimazu et al., 1999). TLR 3, 
5, 7, and 9 recognize viral double-stranded (ds) and single stranded (ss) RNA 
(Alexopoulou et al., 2001), bacterial flagellin (Hayashi et al., 2001), viral 
single-stranded (ss) RNA (Heil et al., 2004; Diebold et al., 2004) and viral and bacterial 
CpG DNA (Hemmi et al., 2001). TLR10 is an orphan receptor involved in induction of 
innate immune responses to influenza virus infection (Lee et al., 2014).  
The recognition of microbial pathogens and their components by TLRs triggers the 
activation of intracellular signaling pathways that result in the production of 
inflammatory mediators such as nitric oxide (NO), prostaglandins, cytokines such as 
tumor necrosis factor (TNF)-, interleukin (IL)-6, and IL-1β, interferon-gamma (IFN-), 
and chemokines. TLRs are type I integral membrane glycoproteins characterized by 
extracellular domains containing varying numbers of leucine-rich-repeat (LRR) motifs 
and a cytoplasmic signaling domain homologous to that of the interleukin 1 receptor 
(IL-1R) termed the Toll/IL-1R homology (TIR) domain. After ligand binding, TLRs 
dimerize and undergo conformational changes required for the recruitment of 
TIR-domain adaptor molecules to the TIR domain of the TLR (Akira et al., 2006). 
There are four adaptor molecules, myeloid differentiation factor 88 (MyD88) 
(Medzhitov et al., 1998), TIR-associated protein (TIRAP) (Yamamoto et al., 2002a; 
Fitzgerald et al., 2001), TIR-domain-containing adaptor protein-inducing IFN-β (TRIF), 
TIR-domain-containing molecule 1 (TICAM1) (Hoebe et al., 2003; Yamamoto et al., 
2003; Oshiumi et al, 2003; Sugiyama et al, 2003), and TRIF-related adaptor molecule 
(TRAM) (Yamamoto et al., 2003). MyD88 is critical for signaling by all TLRs except 
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TLR3. After stimulation, MyD88 associates with the cytoplasmic domain of TLRs and 
recruits IL-1 receptor-associated kinase 1 (IRAK-1) and IRAK-4 (Medzhitov et al., 
1998; Suzuki et al., 2002; Thomas et al., 1999). These mediate activation of NF-κB, 
resulting in the induction of inflammatory mediators. TIRAP mediates 
MyD88-dependent signaling (Yamamoto et al., 2002a; Fitzgerald et al., 2001), and 
TRIF is required for MyD88-independent signaling and involved in both TLR3 and 
TLR4 signaling (Yamamoto et al., 2003; Oshiumi et al., 2003). TRIF stimulation results 
in the activation of NF-κB and IFN regulatory factor 3 (IRF3), and induces the 
expression of inflammatory cytokines and type I IFN (Yamamoto et al., 2002b). TRAM, 
which bridges TLR4 and TRIF, is a specific adaptor for TLR4 and transmits its 
signaling to TRIF (Yamamoto et al., 2003). Thus, TLRs stimulated with microbial 
components activate intracellular signaling by interacting with adaptors that induce the 
production of inflammatory mediators.  
The initiation of the innate immune response through TLR4 triggers an inflammatory 
cascade that is the principal cause of the adverse conditions that occur in sepsis. 
Consequently, TLR4 is a promising therapeutic target for the treatment of sepsis (Opal 
et al., 2002, Lynn et al., 2004). To clarify the molecular mechanism of action of 
TAK-242, the effects of TAK-242 on TLR signaling were investigated in this study. It 
was demonstrated that TAK-242 is a potent and selective inhibitor of TLR4 signaling. 
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2. Materials and Methods 
2.1. Materials 
TAK-242 (Ethyl  (6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1 
-carboxylate)) was synthesized at Takeda Pharmaceutical Company (Fig. 2-2.). 
Ultra-pure LPS (from Escherichia coli serotype O111:B4) was purchased from 
Invivogen (SanDiego, CA). Peptidoglycan (from Staphylococcus aureus) was from 
Fluka (Buchs, Switzerland). Phosphorothioate-stabilized CpG oligodeoxynucleotides 
(ODN) (TCC-ATG-ACG-TTC-CTG-ATG-CT as a ligand for mouse TLR9, 
TCG-TCG-TTT-TGT-CGT-TTT-GTC-GTT as a ligand for human TLR9) were 
synthesized at Hokkaido System Science (Sapporo, Japan). Flagellin was from 
Invivogen. Pam3CSK4 was from Bachem AG (Bubendorf, Switzerland).  
Polyinosinic-polycytidylic acid (poly(I:C)) was from Sigma. R-848 was from 
GLSynthesis Inc. (Worcester, MA). Recombinant mouse IFN- was from Genzyme 
(Minneapollis, MN). Phorbol myristate acetate (PMA) was from Wako (Osaka, Japan). 
 
2.2. Cells 
Mouse RAW264.7 cells were purchased from American Type Culture Collection 
(Manassas, VA, USA). Human U-937 cells were purchased from Dainippon Sumitomo 
Pharmaceutical (Osaka, Japan). Human P31/FUJ cells were purchased from Japanese 
Collection of Research Bioresources (Osaka, Japan). These cells were maintained in 
RPMI-1640 medium supplemented with 10 % inactivated fetal calf serum and 50 g/ml 
gentamycin (Invitrogen, USA). Human embryonic kidney (HEK) 293 cells were 
purchased from Dainippon Sumitomo Pharmaceutical (Osaka, Japan) and maintained in 
Dulbecco’s modified Eagle medium supplemented with 10% inactivated fetal calf serum 
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and 50 g/ml gentamycin. 
 
2.3. Plasmids 
cDNAs encoding human TLR1, human TLR2, human TLR3, human TLR4, mouse 
TLR4, human TLR6, human TLR7, human TLR9, human CD14, human MD2, mouse 
MD2, human MyD88, human TIRAP, human TRIF, and human TRAM were isolated by 
polymerase chain reaction (PCR) and subcloned into a mammalian expression vector, 
pcDNA3.1 (Invitrogen, USA). Human TLR5 expression vector, pUNO- human TLR5 
was purchased from Invivogen. The transmembrane and the intracellular domain of 
mouse TLR4 (amino acid residue 623 to 835) or human TLR4 (amino acid residue 632 
to 839) were fused to the extracellular domain of mouse CD4 (amino acid residue 1 to 
384). The chimera receptors were ligated into a mammalian expression vector 
pMSRneo, which contained SR promoter. All constructions identified by PCR were 
verified by sequencing. 
 
2.4. Measurement of nitrite  
RAW264.7 cells were seeded in 96-well plates at 1  105 cells per well. After 24 h 
culture, cells were incubated with TAK-242 for 1 h, subsequently stimulated with each 
ligands for TLRs, 1 or 10 ng/ml LPS for TLR4, 10 or 100 ng/ml Pam3CSK4 for 
TLR2/TLR1, 1 or 10 g/ml Peptidoglycan for TLR2/TLR6, 1 or 10 g/ml poly(I:C) for 
TLR3, 1 or 10 M R-848 for TLR7, or 0.1 or 1 M CpG ODN for TLR9 in the 
presence of 0.1 ng/ml mouse IFN- for 24 h. The concentrations of nitrite, a stable 
metabolite of nitric oxide (NO), in culture medium were determined with a fluorescent 
reagent, 2,3-diaminonaphthalene (Dojindo, Japan). The fluorescence (Excitation 355nm, 
  
41 
 
Emission 460nm) was detected with Arvo 1420 multilabel counter (Perkinelmer, USA). 
The concentration (IC50 value) of the test compound necessary for 50% inhibition of 
NO production was calculated using the least-squares linear regression.  
 
2.5. Measurement of TNF- 
 RAW264.7 cells were seeded in 96-well plates at 1  105 cells per well. After culture 
for 24 h, cells were incubated with TAK-242 for 1 h, subsequently stimulated with 10 
ng/ml ultra-pure LPS for 24 h. U-937 or P31/FUJ cells were seeded in 96-well plates at 
4  104 cells per well. After culture for 24 h, cells were added 100 nM PMA (Wako, 
Japan) for differentiation into macrophages. After culture for 48 h, cells were incubated 
with TAK-242 for 1 h, subsequently stimulated with 10 ng/ml ultra-pure LPS for 24 h. 
The concentrations of TNF- in culture medium were determined with human or mouse 
TNF- ELISA kits. The concentrations (IC50 values) of the test compound necessary for 
50% inhibition of TNF- production were calculated using the least-squares linear 
regression.  
 
2.6.1. Reporter gene assay for ligand-dependent signaling by TLRs 
HEK293 cells were seeded in 96-well opaque plates at 2  104 cells per well. After 
culture for 24 h, cells were transiently transfected with 30 ng of TLR expression vectors 
or empty vector (pcDNA3.1), 10 ng of pNF-B-luc (Stratagene, USA) and 10 ng of an 
internal control plasmid phRL-TK (Promega) using FuGENE 6 reagent (Roche, USA).  
For expression of TLR4/MD2/CD14 complex, cells were transiently transfected with 5 
ng of TLR4 expression vector or empty vector, 10 ng of pNF-B-luc, 10 ng of an 
internal control plasmid phRL-TK, 12.5 ng of MD-2 and 12.5 ng of CD14 expression 
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vectors using FuGENE 6 reagent. For expression of TLR1/TLR2 and TLR2/TLR6, cells 
were transiently transfected with each 15 ng of TLR expression vectors, 10 ng of 
pNF-B-luc, 10 ng of phRL-TK using FuGENE 6 reagent. After transfection, cells were 
cultured for 24 h. Then, cells were incubated in serum-free medium and various 
concentrations of TAK-242 were added to the wells. After incubation for 30 min, cells 
were stimulated by each TLR ligands, 1 or 10 ng/ml ultra-pure LPS for TLR4, 10 or 100 
ng/ml Pam3CSK4 for TLR2/TLR1, 100 or 1000 ng/ml Peptidoglycan for TLR2/TLR6, 1 
or 10 g/ml poly(I:C) for TLR3, 10 or 100 ng/ml flagellin for TLR5, 1 or 10 M R-848 
for TLR7, or 0.1 or 1 M CpG ODN for TLR9 and then incubated for 4 h. The 
luciferase activities were measured using Dual-Glo
 
luciferase assay system (Promega). 
Transfection efficiencies were normalized to luciferase activity derived from Renilla 
reniformis. The luminescence was detected with Arvo 1420 multilabel counter 
(Perkinelmer, USA). The concentrations (IC50 values) of the test compound necessary 
for 50% inhibition of NF-B activity were calculated using the least-squares linear 
regression.  
 
2.6.2. Reporter gene assay for ligand-independent signaling by TLR4, CD4-TLR 
or adaptors 
HEK293 cells were seeded in 96-well opaque plates at 2  104 cells per well. After 
culture for 24 h, cells were transiently transfected with 30 ng of TLR4, CD4-TLR4 or 
adaptors (MyD88, TRIF, TRAM and TIRAP) expression vector or empty vector, 10 ng 
of pNF-B-luc and 10 ng of an internal control plasmid phRL-TK per well using 
FuGENE 6 reagent. After transfection, various concentrations of TAK-242 were added 
to the wells and further incubated for 24 h. The luciferase activities were measured 
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using Dual-Glo
 
luciferase assay system. Transfection efficiencies were normalized to 
luciferase activity derived from Renilla reniformis. The luminescence was detected with 
Arvo 1420 multilabel counter (Perkinelmer, USA). The concentrations (IC50 values) of 
the test compound necessary for 50% inhibition of NF-B activity were calculated using 
the least-squares linear regression.  
 
2.7. Western blot analysis 
Transfected cells were harvested in cell lysis buffer (Cell signaling technology, Inc, 
USA). After incubation at 4 °C for 15 min, the lysate was mixed with an equal volume 
of a sample buffer (Daiichi Pure Chemicals Co., Ltd., Japan) and heated at 60 °C for 5 
min. Proteins were electrophoresed on sodium dodecyl sulfate (SDS)-polyacrylamide 
gels with Tris-glycine running buffer and electrically transferred onto Clear Blot 
Membrane P (Atto, Japan), which was followed by incubating with 5% (w/v) bovine 
serum albumin in TBS (tris buffered saline)/Tween20. After incubation at 4 °C 
overnight, the membrane was washed and then incubated at room temperature with 
anti-CD4 (Santa  Cruz biotechnology, Inc. USA). After incubation for 1 h, the 
membrane was incubated at room temperature with horseradish peroxidase-conjugated 
secondary antibody for 1 h and then visualized by using ECL Plus western blotting 
detection reagents (GE Healthcare, USA). Horseradish peroxidase-conjugated anti- 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Santa  Cruz biotechnology, 
Inc.) was used as an internal control. 
 
2.8. Statistical analysis 
Data are expressed as the mean ± standard error of the mean (S.E.M.). Differences 
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between means were analyzed using t-test. IC50 values for TAK-242 were determined as 
the concentration showing 50% of control using the least-squares linear regression. All 
calculations were carried out with the SAS system. 
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3.  Results 
3.1. Selectivity of TAK-242 against TLR ligands in mouse RAW264.7cells 
To evaluate if the prevention of LPS-induced inflammation by TAK-242 is caused by 
inhibition of TLR4 signaling, we examined the effects of TAK-242 on signaling 
mediated by ultra-pure LPS as a TLR4-specific ligand in this study. The selectivity of 
TAK-242 against TLR ligands was determined by measuring NO production from 
mouse RAW264.7 cells. The induction of NO production was studied with various TLR 
ligands, including ultra-pure LPS (TLR4-specific ligand), Pam3CSK4 (TLR2/1 ligand), 
peptidoglycan (TLR2/6 ligand), poly(I:C) (TLR3 ligand), R-848 (TLR7 ligand), and 
CpG DNA (TLR9 ligand) with 0.1 ng/ml IFN-. TAK-242 selectively inhibited 
ultra-pure LPS-induced NO production (Fig. 2-3A). In contrast, TAK-242 showed little 
effect on NO production induced by TLR2/1, TLR2/6, TLR3, TLR7 or TLR9 ligands at 
doses as high as 1 M (Fig. 2-3B-F). As shown in Fig. 2-3G, TAK-242 potently 
inhibited NO production from RAW264.7 cells stimulated with 10 ng/ml ultra-pure LPS 
in a dose-dependent manner with an IC50 value of 5.5 nM.  
 
3.2. Effect of TAK-242 on TNF- production from human and mouse 
macrophages stimulated with a TLR4-specific ligand 
To examine the effects of TAK-242 on TNF- production from human and mouse 
macrophages stimulated with ultra-pure LPS, the inhibitory activity for TAK-242 was 
evaluated using human U-937, human P31/FUJ, or mouse RAW264.7 cells. The 
concentration of TNF- released from LPS-stimulated (10 ng/ml) U-937, P31/FUJ, and 
RAW264.7 cells was 7.0 ng/ml, 3.5 ng/ml, and 3.0 ng/ml, respectively (data not shown). 
In human U-937 and P31/FUJ cells, TAK-242 inhibited LPS-mediated TNF- 
production in a dose-dependent manner, with IC50 values of 52 nM and 37 nM, 
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respectively (Fig. 2-4). In mouse RAW264.7 cells, the IC50 value for inhibition of 
TNF- production by TAK-242 treatment was 4.8 nM. TAK-242 showed potent 
inhibition of inflammatory cytokine production from both mouse and human 
macrophages stimulated with a TLR4-specific ligand, although the inhibitory activity in 
the mouse macrophage cell line was 7.7 to 11-fold greater than observed in human cell 
lines. 
 
3.3. Selectivity of TAK-242 against recombinant TLRs 
 To confirm the results obtained in macrophages, we constructed an NF-B reporter 
gene assay system with HEK293 cells transiently expressing the following recombinant 
TLRs, TLR2/l, TLR2/6, TLR3, TLR4, TLR5, TLR7 or TLR9. The expressed TLRs 
activated NF-B by the addition of their cognate ligands (Fig. 2-5A-H). To detect the 
activation of TLR4 by LPS, its co-receptors, CD14 and MD2, were co-expressed with 
TLR4. TAK-242 (1 M) inhibited NF-B activation induced by LPS in HEK293 cells 
expressing human TLR4, human MD2 and human CD14 (Fig. 2-5A) and in cells 
expressing mouse TLR4, mouse MD2 and human CD14 (Fig. 2-5B). In the absence of 
co-expression of CD14 and MD2, TLR4 was not activated by LPS (data not shown). In 
contrast, TAK-242 did not inhibit other TLRs such as TLR2/l, TLR2/6, TLR3, TLR5, 
TLR7, or TLR9 at doses as high as 1 M (Fig. 2-5C-H). The IC50 values of 
LPS-induced NF-B activation for TAK-242 in HEK293 cells expressing human TLR4, 
human MD2, and human CD14, or mouse TLR4, mouse MD2, and human CD14 were 
110 nM and 15 nM, respectively (Fig. 2-5I). This result is consistent with the 
observation that TAK-242 had a greater inhibitory effect on mediator production in 
LPS-stimulated mouse cells than human cells.  
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3.4. Effect of TAK-242 on ligand-independent signaling of TLR4 
 TLR4 has been shown to activate ligand-independent signaling (Lee et al, 2004). As 
shown in Fig. 2-6A, both human and mouse TLR4 showed constitutive activation of 
NF-B in the absence of MD2 and CD14. The effect of TAK-242 on ligand-independent 
TLR4 signaling was examined with this assay system. TAK-242 (1 M) inhibited 
ligand-independent activation of NF-B mediated by over-expression of human or 
mouse TLR4. This result indicated that TAK-242 does not affect the function of MD2 or 
CD14. The IC50 values of ligand-independent NF-B activation by human TLR4 or 
mouse TLR4 for TAK-242 were 310 nM and 35 nM, respectively (Fig. 2-6B). Thus, 
TAK-242 potently suppressed ligand-independent signaling by mouse and human 
TLR4. 
 
3.5. Effect of TAK-242 on NF-B activation mediated by adaptors for TLR4.    
After ligand binding, intracellular signaling of TLR4 is mediated by adaptor proteins 
such as MyD88, TIRAP, TRIF, and TRAM (Akira et al., 2006). Expression of these 
adaptors in cells results in the activation of their downstream signaling cascades. To 
examine effects of TAK-242 on MyD88, TIRAP, TRIF, and TRAM, signaling activation 
by transient expression of adaptors for TLR4 in HEK293 cells in the presence of 
TAK-242 was measured using the NF-B reporter gene assay. Transfection of 
expression plasmids for MyD88, TIRAP, TRIF, or TRAM into HEK293 cells led to 
marked activation of NF-B compared to the empty vector control. However, TAK-242 
did not affect signaling from those adaptors (Fig. 2-7). 
 
3.6. Effect of TAK-242 on NF-B activation mediated by a CD4-TLR4 chimera 
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receptor 
To determine the region of TLR4 that interacts with TAK-242, the effect of TAK-242 
on a CD4-TLR4 chimera receptor comprising the extracellular domain of CD4 and the 
intracellular domain of TLR4 was examined with the NF-B reporter gene assay. The 
chimeric CD4-human TLR4 or CD4-mouse TLR4 receptors activated NF-B in 
transiently expressed HEK293 cells (Fig. 2-8A). NF-B activation mediated by 
CD4-human TLR4 or CD4-mouse TLR4 was inhibited by TAK-242 in a 
dose-dependent manner. The TAK-242 IC50 values for the CD4-human TLR4 and 
CD4-mouse TLR4 chimeras were 240 nM and 62 nM, respectively (Fig. 2-8B). To 
examine whether TAK-242 affected expression of chimera receptors in transfected 
HEK293 cells, western blot analysis was performed with antibodies that recognize the 
extracellular domain of CD4. As shown in Fig.2-8C, TAK-242 did not affect the 
expression levels of CD4-human TLR4 or CD4-mouse TLR4 at 1 M. Thus, TAK-242 
showed potent inhibition of signaling mediated by the intracellular domain of TLR4.  
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4. Discussion 
The pathogenesis of sepsis involves a progressive expansion of the systemic 
inflammatory response of the host to a microbial infection (Glauser, 2000). A major 
factor contributing to sepsis is the shedding of LPS from the cell wall of gram-negative 
bacteria into the circulation. LPS interacts with TLR4 expressed on a variety of cell 
types and induces the overproduction of inflammatory cytokines. Systemic release of 
these cytokines induces vascular permeability and disseminated intravascular 
coagulation, which can trigger shock (Annane et al., 2005). TAK-242 is a promising 
drug candidate for the suppression of excessive inflammatory responses in sepsis by 
selective inhibition of TLR4 signaling. Most LPS preparations on the market are 
contaminated with other bacterial components, such as lipoproteins, thus activating 
TLR2 signaling as well as TLR4 signaling. To clarify the effect of TAK-242 on TLR4 
signaling, we used ultra-pure LPS, which was extracted by enzymatic hydrolysis and 
purified by phenol re-extraction (Hirschfeld et al., 2000), thus generating a ligand that 
selectively activates the TLR4 pathway and expression system. Our findings show that 
TAK-242 is a selective inhibitor of TLR4 signaling, which potentiated its efficacy 
against LPS-induced inflammation.  
LPS induces the dimerization of TLR4, and this can trigger ligand-independent 
activation of the receptor. Receptor dimerization is required to activate downstream 
signaling pathways (Lee et al., 2004). In this study, we demonstrated that TAK-242 
suppresses ligand-dependent and -independent signaling by TLR4. These results were 
consistent with our previous study showing that TAK-242 does not inhibit interactions 
between LPS and its receptor in macrophages (Ii et al., 2006). Additionally, results from 
the NF-B reporter gene assay indicated that TLR4 has more constitutive activity than 
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other TLRs. Expression of TLR4 is induced by treatment with various stimulants such 
as IFN-(Faure et al., 2001), IL-10 (Petit-Bertron et al., 2003), IL-2 (Mita et al., 2002), 
or oxidized low-density lipoprotein (Xu et al., 2001). Additionally, TLR4 is expressed at 
high levels in atherosclerosis (Edfeldt et al., 2002) and inflammatory bowel disease 
(IBD) (Cario et al., 2000). Over-expression of TLR4 has been found to activate NF-κB 
in the absence of TLR4 ligands (Fitzgerald et al., 2001). Thus, individuals who exhibit 
enhanced TLR4 expression may be more susceptible to chronic inflammatory 
conditions, and TAK-242 may have potential as a therapy against various types of 
TLR4-mediated chronic inflammation disorders.  
After ligand binding, TLR4 recruits TIR-domain adaptor molecules MyD88, TIRAP, 
TRIF, and TRAM to the TIR domain of TLR4 (Akira et al., 2006). Although TAK-242 
inhibited the production of various mediators from LPS-stimulated macrophages and 
TLR4-mediated NF-B activation, it did not affect signaling mediated by the 
over-expression of these TLR4 adaptors, suggesting that TAK-242 targets molecules 
upstream of the adaptors, including TLR4 itself. 
TLR signaling is conferred by the TIR domain. Signaling mediated by CD4-TLR4 
TIR domain chimeric receptors was inhibited by TAK-242. These results suggest that 
TAK-242 inhibits TLR4 signaling by targeting the intracellular domain of TLR4 and not 
the extracellular domain. TAK-242 also showed greater inhibition of mediator 
production from LPS-stimulated mouse macrophages than human macrophages. This 
species difference in the inhibitory activity for TAK-242 is consistent with reporter gene 
assays using recombinant TLR4, and our previous study with primary cultured cells (Ii, 
et al., 2006). The inhibitory activity for TAK-242 was changed by simple replacement 
of the TIR for TLR4 under the same cellular conditions, whereas the induction of 
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NF-B activity by mouse TLR4 was at same level as seen with human TLR4. This 
result raises the possibility that TAK-242 targets TIR of TLR4. Although the amino acid 
sequence of TIR between human and mouse TLR4 is conserved, the affinity of 
TAK-242 for TLR4 may be affected by a subtle difference in the amino acid sequences 
of TIR. This proposed mechanism was confirmed by analysis showing that TAK-242 
covalently binds to Cys747 in the intracellular domain of TLR4 (Takashima et al., 2009) 
and disrupts the interaction of TLR4 with adaptor molecules (Matsunaga et al., 2011).  
A TLR4 antagonist, E5531, preferentially blocks LPS interaction with TLR4-MD-2, 
but has a weak effect on blocking the interaction of LPS with CD14 (Akashi et al., 
2003). TAK-242, which can also inhibit TLR4-mediated signaling in the absence of 
MD2 and CD14, should have more potential to suppress inflammation induced by 
various TLR4 ligands than other TLR4 antagonists. Sepsis is a leading killer in the 
noncoronary
 
intensive care unit, and remains worldwide health concern (Martin et al., 
2003, Strehlow et al., 2006, Angus et al, 2013). These data suggest that TAK-242 could 
be a novel therapy for the treatment of sepsis. 
In conclusion, we demonstrated that TAK-242 selectively suppresses TLR4-signaling 
by targeting the intracellular domain of TLR4. The hypothesis for the mechanism of 
action of TAK-242 as a treatment for sepsis is described in Fig. 2-9. Although ligands 
from bacteria such as LPS are recognized by the TLR4/CD14/MD2 complex, which is 
expressed on immune cells such as macrophages, TAK-242 suppresses the initiation of 
signal transduction by targeting the intracellular domain of TLR4. The intracellular 
domain of TLR4 plays an important role in signaling via adaptors, MyD88, TIRAP, 
TRIF, and TRAM. Indeed, a single-point mutation in the TIR domain of mouse TLR4 
(Pro712His, the Lps(d) mutation) abolishes the host immune response to LPS (Xu et al., 
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2000). TAK-242 blocks the activation of NF-B, which is a master regulator of 
inflammation, mediated by the TIR domain of TLR4. This inhibitory action results in 
the suppression of inflammatory mediators such as NO, cytokines such as TNF, and 
prostaglandins. These data show that the therapeutic effect of TAK-242 observed in 
LPS-induced sepsis models is due to specific suppression of TLR4-mediated signaling.  
TLR4 signaling pathways are related to human diseases involving innate immunity, 
adaptive immunity, and both innate and adaptive immunity (Cook et al, 2004). TLR4 
has been shown to respond to various endogenous ligands such as heat-shock proteins 
(HSP60, HSP70, gp96, and HSP22), extracellular matrix degradation products 
(Biglycan, hyaluronan, fibronectin extradomain A, and surfactant protein-A), 
high-mobility group box 1 (HMGB-1) protein, oxidized low-density lipoprotein 
(OxLDL), -defensin (Miyake, 2007), and saturated free fatty acids (Lee et al., 2001). 
The interaction of TLR4 with endogenous ligands is involved in the development and 
progression of various human diseases, including inflammation such as arthritis and 
asthma, atherosclerosis, diabetes, and MI (Cook et al., 2004, Shi et al., 2006, Edfeldt et 
al., 2004). Pharmacological manipulation of TLR4 signaling is thought to have great 
therapeutic potential for a variety of disorders. TAK-242 has been reported to show a 
therapeutic effect in diabetes, acute chest syndrome, and scleroderma by other groups 
(Kuno et al., 2009, Ghosh et al., 2013, Bhattacharyya et al., 2014.), and TAK-242 
represents a novel therapeutic approach for the treatment of TLR4-mediated diseases.    
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5. Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1.  TLRs and their signaling pathways 
 
(Revised from Trinchieri G et al., 2007) 
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Fig. 2-2.  Chemical structure of TAK-242     
 
 
 
   
  
 
 
 
 
 
 
 
 
 
 
Fig. 2-3. Effect of TAK-242 on TLR ligands-induced nitric oxide production from 
mouse RAW264.7 cells 
Mouse RAW264.7 cells were stimulated by various TLR ligands, LPS (TLR4 ligand) 
(A) Pam3CSK4 (TLR2/1 ligand) (B) peptidoglycan (TLR2/6 ligand) (C) poly(I:C) 
(TLR3 ligand) (D) R-848 (TLR7 ligand) (E) or CpG ODN (TLR9 ligand) (F) in the 
absence or presence of 1 M TAK-242 (gray bars: vehicle, white bars: 1M TAK-242) 
with 0.1 ng/ml mouse IFN- for 24 h. After incubation, the concentrations of released 
NO in the medium were measured with 2,3-diaminonaphthalene. (G) Dose-dependent 
inhibition of NO production by TAK-242 was measured with RAW264.7 cells 
stimulated with 10 ng/ml ultra-pure LPS. Results are the means ± S.E.M (n=3). *P<0.05 
and ***P<0.001 vs. vehicle.   
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Fig. 2-4. Effect of TAK242 on LPS-induced TNF-production from human U-937, 
P31/FUJ cells and mouse RAW264.7 cells  
Monocytic cell lines, human U-937 (closed circle), human P31/FUJ cells (opened 
circle), or mouse RAW264.7 cells (closed triangle) were incubated with TAK-242 for 1 h, 
subsequently stimulated with 10 ng/ml ultra-pure LPS for 24 h. The concentrations of 
TNF- in the culture medium were determined by ELISA. Results are the 
means ± S.E.M (n=3).  
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Fig. 2-5.  Effect of TAK-242 on NF-B activation mediated by recombinant TLRs 
stimulated with their ligands 
HEK293 cells were transiently co-transfected with an NF-B reporter plasmid, an 
internal control reporter plasmid phRL-TK and the expression plasmids for TLRs, and 
then cultured for 24 h. Cells were incubated with DMSO or 1 M TAK-242 for 30 min, 
followed by adding their ligands, in the absence or presence of TAK-242 (gray bars: 
vehicle, white bars: 1M TAK-242). After 4 h culture, cells were lysed and the NF-B 
reporter activities were measured using Dual-Glo luciferase assay system. Promoter 
activities were normalized to Renilla luciferase activities. (I) Dose-dependent inhibition 
of NF-B activation stimulated with 10 ng/ml LPS by TAK-242 was examined in 
HEK293 cells transiently expressing hTLR4/hMD2/hCD14 (closed square) or 
mTLR4/mMD2/hCD14 (closed triangle). Results are the means ± S.E.M (n=3). *P<0.05, 
**P<0.01 and ***P<0.001 vs. vehicle.   
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Fig. 2-6. Effect of TAK-242 on ligand-independent signaling of TLR4 
(A) HEK293 cells were transiently co-transfected with an NFB reporter plasmid, an 
internal control reporter plasmid phRL-TK and the expression plasmid for human TLR4 
or mouse TLR4, or the empty plasmid pcDNA3.1 and further cultured for 24 h. (B) 
After transfection, cells were cultured in the presence of various concentrations of 
TAK-242. After 24 h culture, cells were lysed and the NF-B reporter activities induced 
by human TLR4 (closed square) or mouse TLR4 (closed triangle) were measured using 
Dual-Glo luciferase assay system. Promoter activities were normalized to Renilla 
luciferase activities. Results are the means ± S.E.M (n=3). ***P<0.001 vs. vehicle.   
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Fig. 2-7. Effect of TAK-242 on NF-B activation mediated by adaptors for TLR4 
HEK293 cells were transiently co-transfected with an NFB reporter plasmid, an 
internal control reporter plasmid phRL-TK and the expression plasmids for adaptors, 
human MyD88, human TIRAP, human TRIF or human TRAM, or empty vector. After 
transfection, cells were cultured in the absence or presence of TAK-242 (gray bars: 
vehicle, white bars: 1M TAK-242) for 24 h. After culture, the NF-B reporter 
activities were measured using Dual-Glo luciferase assay system. Promoter activities 
were normalized to Renilla luciferase activities. Results are the means ± S.E.M (n=3).   
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Fig. 2-8. Effect of TAK-242 on ligand-independent signaling by a CD4-TLR4 
chimera receptor  
(A) HEK293 cells were transiently co-transfected with an NF-B reporter plasmid, an 
internal control reporter plasmid phRL-TK and the expression plasmid for CD4-human 
TLR4, CD4-mouse TLR4, or CD4 and further cultured for 24 h. (B) After transfection, 
cells were cultured in the presence of various concentrations of TAK-242. After 24 h 
culture, cells were lysed and the NF-B reporter activities induced by CD4-human 
TLR4 (closed square) or CD4-mouse TLR4 (closed triangle) were measured using 
Dual-Glo luciferase assay system. Results are the means ± S.E.M (n=3). ***P<0.0001 
vs. vehicle. (C) Expression of CD4-human or mouse TLR4 in transfected HEK293 cells 
in the absence or presence of 1 M TAK-242 was analyzed with western blotting.   
p
c
D
N
A
3
.1
C
D
4
C
D
4
-h
T
L
R
4
C
D
4
-m
T
L
R
4
0
30
60
90
120
150
180
Vehicle
1M TAK-242
*** ***
N
F
-
B
/T
K
  
(R
a
ti
o
)
-9 -8 -7 -6 -5
-25
0
25
50
75
100
125 CD4-hTLR4
CD4-mTLR4
Log[TAK-242](M)
 N
F
-
B
 a
c
ti
v
it
y
 (
%
)
(A) 
(B) 
(C) 
 
        Vector    Human    Mouse 
0    1    0   1    0   1  (M)     
 
CD4-TLR4 
GAPDH 
  
60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2-9. Working hypothesis of therapeutic action of TAK-242 
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General Conclusion 
 
We have characterized the molecular mechanisms of action of two different drug 
candidates, which were identified or optimized using phenotypic assays focusing on the 
development of treatments for myocardial infarction and sepsis. A potential MI drug, 
T-162559, was generated in a cell-based assay that monitors acidosis-induced platelet 
swelling as an NHE inhibitor. It was also shown to have a cardioprotective effect in 
ischemia-reperfusion models (Kusumoto et al., 2002). A potential anti-sepsis drug, 
TAK-242, was identified in a cell-based assay measuring NO and cytokine production 
from LPS-treated macrophage cell lines and also showed a therapeutic effect in septic 
shock models (Sha et al., 2007). Elucidation of the molecular targets and the selectivity 
profiles of these drug candidates is needed for a better understanding of their efficacy, 
particularly in relation to clinical applications and potential side effects. 
 The molecular mechanism of action of T-162559 was described in chapter I. It was 
found that the mechanism of action of T-162559 for the treatment of MI is by inhibition 
of NHE1 isoform. The molecular mechanism of action of TAK-242 was described in 
chapter II. It was shown that the mechanism of action of TAK-242 for the treatment of 
sepsis was by inhibition of TLR4 at its cytoplasmic domain. The phenotypic efficacy 
and the selectivity of both compounds were high, suggesting that their molecular targets, 
NHE1 and TLR4, are centrally responsible for each observed phenotype. By clarifying 
the molecular mechanisms of actions of T-162559 and TAK-242, the results have 
identified druggable targets relevant to the development and pathology of each disease. 
Phenotypic screening strategies offer ways to identify compounds or targets that 
modulate the key characteristics of specific diseases. Advanced technologies, such as 
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chemical proteomics and label-free methods, have been developed for target 
deconvolution of bioactive compounds (Futamura et al., 2013, Salcius et al., 2014). 
However, elucidation of the molecular mechanism of a bioactive compound and the 
target is a challenging issue. Lee et al. suggests that this problem is largely due to the 
fact that most small molecules do not bind to a single target (Lee et al., 2013). In this 
study, elucidation of the molecular mechanism for each compound was achieved by 
applying molecular biological methods based on an understanding of the molecular 
mechanisms of the phenotype and characteristics of the target cells. This was also 
facilitated by the generation of selective compounds with potent activity by medicinal 
chemistry based on data from the phenotypic assays. The generation of potent 
compounds, including covalent binders like TAK-242, can contribute to an increased 
success rate in robust target identification.  
With regard to T-162559, previous pharmacological and chemical information 
enabled an informed prediction of the main target protein. Since T-162559 showed more 
potent and selective inhibition of the NHE1 than caniporide and eniporide, this 
compound could offer a superior therapeutic approach for the treatment of MI and other 
NHE1-mediated diseases. In contrast, TLR4-selective inhibitors that act via the 
intracellular domain, like TAK-242, have not been reported yet. In general, 
one-transmembrane receptors, including TLRs, are not accepted as chemical therapeutic 
targets due to low druggability. However, discovery of TAK-242 was achieved because 
a phenotypic screening approach was used, which enabled comprehensive screening of 
drugs targeting molecules involved in the phenotype, resulting in the discovery of 
TAK-242. TAK-242 should open new opportunities for TLR-targeted drug discovery. 
We believe that improving the productivity of drug and target discovery requires a 
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more balanced or combined strategy that utilizes both target-oriented and phenotypic 
approaches. Information on the molecular mechanism of action can facilitate a 
target-oriented high-throughput screening campaign to identify other chemotypes with 
more desirable properties and different mechanisms of inhibition. The established 
methods that were described and used in these studies are applicable for screening of 
drugs targeting ion transporters or TLRs. Furthermore, the identified chemical probes 
for NHE1 and TLR4 are useful not only for the development of drugs, but also for 
better characterization of their biological roles. 
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